Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells
- PMID: 10455328
- PMCID: PMC1566138
- DOI: 10.1038/sj.bjp.0702673
Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells
Abstract
1. The aim of the present study was to characterize functional responses to ropinirole, its major metabolites in man (SKF-104557 (4-[2-(propylamino)ethyl]-2-(3H) indolone), SKF-97930 (4-carboxy-2-(3H) indolone)) and other dopamine receptor agonists at human dopamine D2(long) (hD2), D3 (hD3) and D4.4 (hD4) receptors separately expressed in Chinese hamster ovary cells using microphysiometry. 2. All the receptor agonists tested (ropinirole, SKF-104557, SKF-97930, bromocriptine, lisuride, pergolide, pramipexole, talipexole, dopamine) increased extracellular acidification rate in Chinese hamster ovary clones expressing the human D2, D3 or D4 receptor. The pEC50s of ropinirole at hD2, hD3 and hD4 receptors were 7.4, 8.4 and 6.8, respectively. Ropinirole is therefore at least 10 fold selective for the human dopamine D3 receptor over the other D2 receptor family members. 3. At the hD2 and hD3 dopamine receptors all the compounds tested were full agonists as compared to quinpirole. Talipexole and the ropinirole metabolite, SKF-104557, were partial agonists at the hD4 receptor. 4. Bromocriptine and lisuride had a slow onset of agonist action which precluded determination of EC50s. 5. The rank order of agonist potencies was dissimilar to the rank order of radioligand binding affinities at each of the dopamine receptor subtypes. Functional selectivities of the dopamine receptor agonists, as measured in the microphysiometer, were less than radioligand binding selectivities. 6. The results show that ropinirole is a full agonist at human D2, D3 and D4 dopamine receptors. SKF-104557 the major human metabolite of ropinirole, had similar radioligand binding affinities to, but lower functional potencies than, the parent compound.
Figures







Similar articles
-
Pharmacological characterization of extracellular acidification rate responses in human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.Br J Pharmacol. 1999 Jul;127(5):1135-44. doi: 10.1038/sj.bjp.0702657. Br J Pharmacol. 1999. PMID: 10455259 Free PMC article.
-
Comparative pharmacological study of ropinirole (SKF-101468) and its metabolites in rats.J Pharm Pharmacol. 2000 Sep;52(9):1129-35. doi: 10.1211/0022357001774895. J Pharm Pharmacol. 2000. PMID: 11045894
-
Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors.Mol Pharmacol. 1994 Jan;45(1):51-60. Mol Pharmacol. 1994. PMID: 8302280
-
Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance.Parkinsonism Relat Disord. 2009 Dec;15 Suppl 4:S2-7. doi: 10.1016/S1353-8020(09)70826-0. Parkinsonism Relat Disord. 2009. PMID: 20123551 Review.
-
Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance.Curr Opin Pharmacol. 2010 Feb;10(1):100-7. doi: 10.1016/j.coph.2009.10.001. Epub 2009 Nov 5. Curr Opin Pharmacol. 2010. PMID: 19896900 Review.
Cited by
-
Pramipexole extended-release: a review of its use in patients with Parkinson's disease.Drugs. 2014 Dec;74(18):2175-90. doi: 10.1007/s40265-014-0322-5. Drugs. 2014. PMID: 25385556 Review.
-
Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds.Cell Signal. 2018 Jan;41:75-81. doi: 10.1016/j.cellsig.2017.07.003. Epub 2017 Jul 14. Cell Signal. 2018. PMID: 28716664 Free PMC article. Review.
-
Activation of G proteins and extracellular signal-regulated kinase 1/2 phosphorylation via human dopamine D4.4 receptors: differential pathway-dependent potencies of receptor agonists.Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):87-99. doi: 10.1007/s00210-008-0333-4. Epub 2008 Aug 6. Naunyn Schmiedebergs Arch Pharmacol. 2009. PMID: 18682919
-
Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors.Br J Pharmacol. 2015 Feb;172(4):1124-35. doi: 10.1111/bph.12988. Epub 2015 Jan 13. Br J Pharmacol. 2015. PMID: 25339241 Free PMC article.
-
Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.Psychopharmacology (Berl). 2007 Apr;191(3):767-82. doi: 10.1007/s00213-006-0567-0. Epub 2006 Sep 19. Psychopharmacology (Berl). 2007. PMID: 17047933
References
-
- ARIANO M.A., SIBLEY D.R. Dopamine receptor distribution in the rat CNS; elucidation using anti-peptide antisera directed against the D1A and D3 subtypes. Brain Res. 1994;649:95–110. - PubMed
-
- BOWEN W.P., COLDWELL M.C., HICKS F.R., RILEY G.J. Further characterisation of human D2 and D3 receptors–GppNHp shifts are explained by the presence of more than one binding site in each clone. Br. J. Pharmacol. 1993;108:277P.
-
- BOWEN W.P., JERMAN J.C. Nonlinear regression using spreadsheets. Trends Pharm. Sci. 1995;16:413–417. - PubMed
-
- BOYFIELD I., WINN F., COLDWELL M.C. Comparison of agonists potencies at human D2 and D3 receptors, expressed in the same cell line, using the Cytosensor Microphysiometer. Biochem. Soc. Trans. 1996;24:57S. - PubMed
-
- BURRIS K.D., PACHECO M.A., FILTZ T.M., KUNG M.-P., KUNG H.F., MOLINOFF P.B. Lack of discrimination by agonists for D2 and D3 dopamine receptors. Neuropsychopharmacology. 1995;12:335–345. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources